Breyanzi in Pakistan

Breyanzi - overview

Breyanzi (lisocabtagene maraleucel) is manufactured by BMS and indicated for DLBCL, CLL/SLL, FL, MCL. It is a CAR-T (CD19) approved by the US FDA in 2021 and may be accessible to patients in Pakistan through a Named Patient Program or personal-import pathway.

Access in Pakistan

Pakistan's DRAP permits personal-use import of unregistered specialty drugs; documentation-heavy process.

How Reserve Meds coordinates access in Pakistan

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Pakistan-specific eligibility.
3. Treating physician in Pakistan issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Breyanzi from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Pakistan.

Typical timeline for Pakistan

End-to-end, most requests are completed in 2-6 weeks. Pakistan's tier 2 regulatory maturity typically supports moderate processing times.

What patients and physicians in Pakistan ask

• Is the pathway legal in Pakistan? Yes - it operates under Pakistan's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in Pakistan able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Breyanzi in Pakistan

Join the Breyanzi waitlist